RSS | Login | Register

Marc Iskowitz

Recent Articles

Wolters Kluwer deals health analytics unit to private equity firm

May 15, 2012

Symphony Technology Group, a private equity firm, acquired the healthcare analytics business of Wolters Kluwer, the companies said.

Pharma Report 2012: Get Back in Shape

May 01, 2012

When big pharma looks in the mirror, what does it see? A body beset by old, expiring brands and not enough energetic, youthful ones to replace them. Marc Iskowitz has industry's regimen for regaining form

Social media's strengths as source of info

May 01, 2012

FDA issues may deter drugmakers from engaging in social media, but that's no excuse to ignore what audiences are saying on these platforms

NACCME to run health congress

May 01, 2012

Accredited medical education and communications firm NACCME acquired CME LLC, which operates the US Psychiatric & Mental Health Congress.

Poll: MDs open to more eCME use

May 01, 2012

A survey of 971 physicians showed that, while most said they would prefer to take CME training online, only 6.4% actually participate in virtual training or any type of virtual event very often.

Med Ed Report briefs: May 2012

May 01, 2012

News on Sunshine Act, Viscira, CBI, Stanford Medical School, Cutting Edge Information

Campbell introduces Encuity venture

May 01, 2012

Biopharma consultancy Campbell Alliance launched a market research and analytics group, one that could pose a threat to traditional MR firms.

Vivus in talks to out-license ED drug Stendra

April 30, 2012

Rather than test the waters for faster-than-Viagra drug Stendra, Vivus wants another firm to handle marketing.

Bydureon catching on among endos but low profits expected, Amylin says

April 26, 2012

Amylin said weekly diabetes shot Bydureon, launched in February, is gaining market share among influential physicians but expects the med's profit margins to be low for some time.

Rathmann, biotech giant, banked Amgen on EPO drugs

April 25, 2012

George Rathmann, Amgen's founding CEO and a forerunner of the modern biotech executive, died Sunday. He is credited with steering the firm deeply into EPO drugs, a long-lived cash cow which is only now showing its age, first-quarter earnings show.

« Previous

Video Exclusive

Web Exclusives

Five industry experts advise specialty pharma company on digital strategy

April 20, 2012

Specialty pharma company POZEN assembled a crack team of experts to help shape its digital strategy. Not only did POZEN share with us the text from their contributions, but you can watch exclusive video clips of their valuable perspectives right here.